Literature DB >> 35300085

Heterobifunctional Compounds as BRAF Degraders for Treating Cancer.

Ram W Sabnis1.   

Abstract

Entities:  

Year:  2022        PMID： 35300085      PMCID： PMC8919278          DOI： 10.1021/acsmedchemlett.2c00039

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN： 1948-5875            Impact factor:   4.345


× No keyword cloud information.
  6 in total

1.  RAF-MEK-ERK pathway in cancer evolution and treatment.

Authors:  Rahim Ullah; Qing Yin; Aidan H Snell; Lixin Wan
Journal:  Semin Cancer Biol       Date:  2021-05-13       Impact factor: 15.707

Review 2.  E2-E3 ubiquitin enzyme pairing - partnership in provoking or mitigating cancers.

Authors:  Shu-Chun Chang; Bo-Xiang Zhang; Jeak Ling Ding
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2022-01-22       Impact factor: 10.680

Review 3.  Recent Developments in PROTAC-Mediated Protein Degradation: From Bench to Clinic.

Authors:  Zhenyi Hu; Craig M Crews
Journal:  Chembiochem       Date:  2021-09-23       Impact factor: 3.461

Review 4.  The rapidly evolving landscape of novel targeted therapies in advanced non-small cell lung cancer.

Authors:  Barbara Melosky; Paul Wheatley-Price; Rosalyn A Juergens; Adrian Sacher; Natasha B Leighl; Ming-Sound Tsao; Parneet Cheema; Stephanie Snow; Geoffrey Liu; Paul B Card; Quincy Chu
Journal:  Lung Cancer       Date:  2021-06-05       Impact factor: 5.705

Review 5.  Major Advances in Targeted Protein Degradation: PROTACs, LYTACs, and MADTACs.

Authors:  Shanique Alabi; Craig Crews
Journal:  J Biol Chem       Date:  2021-04-08       Impact factor: 5.157

Review 6.  Emerging agents that target signaling pathways to eradicate colorectal cancer stem cells.

Authors:  Valdenizia R Silva; Luciano de S Santos; Rosane B Dias; Claudio A Quadros; Daniel P Bezerra
Journal:  Cancer Commun (Lond)       Date:  2021-11-17
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.